∙ Lupin receives tentative approval from USFDA for Tolvaptan tablets. ∙ Tolvaptan Tablets had estimated annual sales of $287 mn in the US.
∙ Organic business delivered steady performance with mid-single digit volume growth. ∙ Home care volumes grew in mid-single digit; personal care grew in low-single digit. ∙ Indonesia biz to improve further, with double-digit volume & value growth.
∙ Total – Standalone business down 13% YoY, volume up 11% YoY. ∙ Edible oil business down 19% YoY, volume up 5% YoY. ∙Food & FMCG business up 25% YoY, volume up 18% YoY.